Literature DB >> 17459012

Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy.

N Komatsu1, K Saijoh, C Kuk, F Shirasaki, K Takehara, E P Diamandis.   

Abstract

BACKGROUND: Human tissue kallikreins (KLKs) are a family of 15 trypsin-like or chymotrypsin-like secreted serine proteases (KLK1-KLK15). Multiple KLKs have been quantitatively identified in normal stratum corneum (SC) and sweat as candidate desquamation-related proteases.
OBJECTIVES: To quantify KLK5, KLK6, KLK7, KLK8, KLK10, KLK11, KLK13 and KLK14 in the SC and serum of patients with psoriasis, and their variation between lesional and nonlesional areas and with phenotype, therapy and severity. The overall SC serine protease activities were also measured.
METHODS: Enzyme-linked immunosorbent assays and enzymatic assays were used.
RESULTS: The lesional SC of psoriasis generally contained significantly higher levels of all KLKs. KLK6, KLK10 and KLK13 levels were significantly elevated even in the nonlesional SC. The overall trypsin-like, plasmin-like and furin-like activities were significantly elevated in the lesional SC. Plasmin-like activity was significantly elevated also in the nonlesional SC. The SC chymotrypsin-like activity was only slightly elevated in psoriasis. KLK7 serum levels did not differ between normal volunteers and patients with psoriasis. Serum KLK6, KLK8, KLK10 and KLK13 levels in patients with untreated psoriasis significantly correlated with Psoriasis Area and Severity Index score. Serum KLK5 and KLK11 levels decreased in patients with psoriasis after therapy, especially with etretinate. Patients with erythrodermic psoriasis exhibited significantly higher serum KLK levels than normal subjects or patients with psoriasis vulgaris or arthropathic psoriasis.
CONCLUSIONS: We found aberrant KLK levels in the SC and serum of patients with psoriasis and suggest that KLKs might be involved in the pathogenesis of this disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17459012     DOI: 10.1111/j.1365-2133.2006.07743.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  14 in total

Review 1.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

2.  Visualizing protein-ligand binding with chemical energy-wise decomposition (CHEWD): application to ligand binding in the kallikrein-8 S1 Site.

Authors:  Saad Raza; Kara E Ranaghan; Marc W van der Kamp; Christopher J Woods; Adrian J Mulholland; Syed Sikander Azam
Journal:  J Comput Aided Mol Des       Date:  2019-04-15       Impact factor: 3.686

3.  Kallikrein-related peptidase-8 (KLK8) is an active serine protease in human epidermis and sweat and is involved in a skin barrier proteolytic cascade.

Authors:  Azza Eissa; Vanessa Amodeo; Christopher R Smith; Eleftherios P Diamandis
Journal:  J Biol Chem       Date:  2010-10-12       Impact factor: 5.157

Review 4.  Protease and protease-activated receptor-2 signaling in the pathogenesis of atopic dermatitis.

Authors:  Sang Eun Lee; Se Kyoo Jeong; Seung Hun Lee
Journal:  Yonsei Med J       Date:  2010-11       Impact factor: 2.759

5.  Expression and function of the kallikrein-related peptidase 6 in the human melanoma microenvironment.

Authors:  Stefanie Krenzer; Heike Peterziel; Cornelia Mauch; Sachiko I Blaber; Michael Blaber; Peter Angel; Jochen Hess
Journal:  J Invest Dermatol       Date:  2011-07-14       Impact factor: 8.551

6.  Inhibition of transcription factor specificity protein 1 alters the gene expression profile of keratinocytes leading to upregulation of kallikrein-related peptidases and thymic stromal lymphopoietin.

Authors:  Lianghua Bin; Byung E Kim; Clifton F Hall; Sonia M Leach; Donald Y M Leung
Journal:  J Invest Dermatol       Date:  2011-07-14       Impact factor: 8.551

Review 7.  Involvement of Kallikrein-Related Peptidases in Normal and Pathologic Processes.

Authors:  Ana Carolina B Stefanini; Bianca Rodrigues da Cunha; Tiago Henrique; Eloiza H Tajara
Journal:  Dis Markers       Date:  2015-12-09       Impact factor: 3.434

8.  Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold - A Potential Therapeutic Intervention for Skin Diseases.

Authors:  Wenjie Chen; Veronica A Kinsler; Derek Macmillan; Wei-Li Di
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

9.  Molecular and Cellular Profiling of Scalp Psoriasis Reveals Differences and Similarities Compared to Skin Psoriasis.

Authors:  Juan Ruano; Mayte Suárez-Fariñas; Avner Shemer; Margeaux Oliva; Emma Guttman-Yassky; James G Krueger
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

10.  Important role of kallikrein 6 for the development of keratinocyte proliferative resistance to topical glucocorticoids.

Authors:  Mari Kishibe; Gleb Baida; Pankaj Bhalla; Robert M Lavker; Bethanee Schlosser; Sin Iinuma; Shigetaka Yoshida; Joel T Dudley; Irina Budunova
Journal:  Oncotarget       Date:  2016-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.